{'fraction_non_alphanumeric': 0.015220700152207, 'fraction_numerical': 0.0, 'mean_word_length': 6.075268817204301, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.

Nine outpatients who met well-defined criteria for probable Alzheimer's disease (AD) and who had significant behavioral agitation failed to improve with neuroleptic therapy and were subsequently treated with carbamazepine. Five patients showed a clear improvement, and one patient an equivocal response according to clinical evaluation and Brief Psychiatric Rating Scale scores; those results suggests that carbamazepine may be useful to treat agitated AD patients who have not previously responded to neuroleptics and patients with other organic mental syndromes.